Diagnosis and management of the metabolic syndrome

The metabolic syndrome has received increased attention in the past few years. This statement from the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) is intended to provide up-to-date guidance for professionals on the diagnosis and management of the metabolic syndrome in adults. The metabolic syndrome is a constellation of interrelated risk factors of metabolic origin—metabolic risk factors—that appear to directly promote the development of atherosclerotic cardiovascular disease (ASCVD).1 Patients with the metabolic syndrome also are at increased risk for developing type 2 diabetes mellitus. Another set of conditions, the underlying risk factors, give rise to the metabolic risk factors. In the past few years, several expert groups have attempted to set forth simple diagnostic criteria to be used in clinical practice to identify patients who manifest the multiple components of the metabolic syndrome. These criteria have varied somewhat in specific elements, but in general they include a combination of both underlying and metabolic risk factors. The most widely recognized of the metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics commonly manifest a prothrombotic state and a proinflammatory state as well. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated serum triglyceride and apolipoprotein B (apoB), increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C). The metabolic syndrome is often referred to as if it were a discrete entity with a single cause. Available data suggest that it truly is a syndrome, ie, a grouping of ASCVD risk factors, but one that probably has more than one cause. Regardless of cause, the syndrome identifies individuals at an elevated risk for ASCVD. The magnitude of the increased risk can vary according to which components of the syndrome are present plus the other, non–metabolic syndrome risk factors in a particular person.

[1]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[2]  G. Leoncini,et al.  Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients , 2005, Journal of internal medicine.

[3]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[4]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[5]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[6]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[7]  R. Andres,et al.  Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging. , 2005, Metabolism: clinical and experimental.

[8]  C. Ballantyne,et al.  Characteristics of US adults with the metabolic syndrome and therapeutic implications , 2004, Diabetes, obesity & metabolism.

[9]  M. Jensen,et al.  Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients. , 2004, European journal of endocrinology.

[10]  B. Franklin,et al.  A cardioprotective "polypill"? Independent and additive benefits of lifestyle modification. , 2004, The American journal of cardiology.

[11]  K. Gauvreau,et al.  Prevalence of the Metabolic Syndrome in American Adolescents: Findings From the Third National Health and Nutrition Examination Survey , 2004, Circulation.

[12]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[13]  S. Jonnalagadda,et al.  Prevalence of Metabolic Syndrome Risk Factors Among Young Adult Asian Indians , 2005, Journal of Immigrant Health.

[14]  Kuninori Shiwaku,et al.  Prevalence of the Metabolic Syndrome using the Modified ATP III Definitions for Workers in Japan, Korea and Mongolia , 2005, Journal of occupational health.

[15]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[16]  M. Hersberger,et al.  Current understanding of the metabolism and biological actions of HDL , 2005, Current opinion in clinical nutrition and metabolic care.

[17]  B. Nicklas,et al.  Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. , 2005, American journal of physiology. Endocrinology and metabolism.

[18]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .

[19]  P. Savage,et al.  Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. , 2004, Diabetes.

[20]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[21]  S. Grundy,et al.  Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. , 2004, The Journal of clinical endocrinology and metabolism.

[22]  Anthony Gamst,et al.  Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey , 2004, Circulation.

[23]  N. Kaplan The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[24]  R M Peshock,et al.  Relationship of Generalized and Regional Adiposity to Insulin Sensitivity in Men With NIDDM , 1996, Diabetes.

[25]  P. Wilson,et al.  Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. , 2004, Endocrinology and metabolism clinics of North America.

[26]  S. Kahn,et al.  Visceral Adiposity Is an Independent Predictor of Incident Hypertension in Japanese Americans , 2004, Annals of Internal Medicine.

[27]  G. Pergola,et al.  Coagulation and fibrinolysis abnormalities in obesity , 2002, Journal of endocrinological investigation.

[28]  P. Jousilahti,et al.  Prevalence of the metabolic syndrome among Omani adults. , 2003, Diabetes care.

[29]  A. Hedley,et al.  The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. , 2005, Diabetes research and clinical practice.

[30]  S. Grundy,et al.  Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. , 1994, JAMA.

[31]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[32]  H. Drexler,et al.  Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. , 2004, Journal of the American College of Cardiology.

[33]  J W Erdman,et al.  AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. , 2000, Circulation.

[34]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[35]  J. Després,et al.  Abdominal obesity and metabolic syndrome , 2006, Nature.

[36]  R. Bergman,et al.  Central Role of the Adipocyte in the Metabolic Syndrome , 2001, Journal of Investigative Medicine.

[37]  J. Callés-Escandon,et al.  Relation of regional fat distribution to insulin sensitivity in postmenopausal women. , 2000, Fertility and sterility.

[38]  C. Rotimi,et al.  Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic americans. , 2000, Annals of epidemiology.

[39]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[40]  Doron Aronson,et al.  How hyperglycemia promotes atherosclerosis: molecular mechanisms , 2002, Cardiovascular diabetology.

[41]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[42]  R. Nesto C‐reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin‐sensitizing treatment with thiazolidinediones , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[43]  B. Goodpaster,et al.  Subcutaneous Abdominal Fat and Thigh Muscle Composition Predict Insulin Sensitivity Independently of Visceral Fat , 1997, Diabetes.

[44]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[45]  Harvey F Lodish,et al.  Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. , 2003, Cytokine & growth factor reviews.

[46]  G. Reaven Role of insulin resistance in human disease (syndrome X): an expanded definition. , 1993, Annual review of medicine.

[47]  A. Garg,et al.  Lipodystrophies: rare disorders causing metabolic syndrome. , 2004, Endocrinology and metabolism clinics of North America.

[48]  S. Kahn,et al.  Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. , 2003, Diabetes care.

[49]  P. Morange,et al.  Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk , 2003, Journal of thrombosis and haemostasis : JTH.

[50]  F. Magrini,et al.  Metabolic syndrome and target organ damage in untreated essential hypertensives , 2004, Journal of hypertension.

[51]  P. Savage,et al.  The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001 , 2004 .

[52]  M. Stern,et al.  The insulin resistance syndrome: the controversy is dead, long live the controversy! , 1994, Diabetologia.

[53]  P. Morange,et al.  The insulin resistance syndrome: implications for thrombosis and cardiovascular disease , 2002, Pathophysiology of Haemostasis and Thrombosis.

[54]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[55]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[56]  Jing Chen,et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.

[57]  A. Rissanen,et al.  Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. , 2004, The Journal of clinical endocrinology and metabolism.

[58]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[59]  J. Nestler,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(4):1929–1935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1045 Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycysti , 2022 .

[60]  C. Ahn,et al.  The Prevalence of the Metabolic Syndrome in Korean Adults: Comparison of WHO and NCEP Criteria , 2005, Yonsei medical journal.

[61]  Jane B Shofer,et al.  Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. , 2004, Diabetes.

[62]  G. Duncan,et al.  Prevalence and trends of a metabolic syndrome phenotype among u.s. Adolescents, 1999-2000. , 2004, Diabetes care.

[63]  S. Grundy,et al.  Relationships of generalized and regional adiposity to insulin sensitivity in men. , 1995, The Journal of clinical investigation.

[64]  E. Poehlman,et al.  Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. , 1999, Diabetes.

[65]  K. Petersen,et al.  Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[66]  D. Chisholm,et al.  The metabolically obese, normal-weight individual revisited. , 1998, Diabetes.

[67]  E. Tai,et al.  Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? , 2004, Diabetes care.

[68]  S. Grundy,et al.  Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.

[69]  D. Rader,et al.  A randomized trial of a low-carbohydrate diet for obesity. , 2003, The New England journal of medicine.

[70]  S. Grundy,et al.  Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. , 2003, The Journal of clinical endocrinology and metabolism.

[71]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[72]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[73]  Aesha Drozdowski,et al.  Standards of medical care in diabetes. , 2004, Diabetes care.

[74]  D. Gaudet,et al.  Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? , 2000, Circulation.

[75]  A. Döring,et al.  Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95 , 2001, Journal of Human Hypertension.

[76]  A. Jenkins,et al.  Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. , 2004, Diabetes care.

[77]  C. Furberg,et al.  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.

[78]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.

[79]  M. Laakso Gene variants, insulin resistance, and dyslipidaemia , 2004, Current opinion in lipidology.

[80]  W. Mitch Beneficial responses to modified diets in treating patients with chronic kidney disease. , 2005, Kidney international. Supplement.

[81]  R. Casamitjana,et al.  The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects , 2005, International Journal of Obesity.

[82]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[83]  H. Rubins Triglycerides and Coronary Heart Disease: Implications of Recent Clinical Trials , 2000, Journal of cardiovascular risk.

[84]  B. Duncan,et al.  Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). , 2004, The American journal of cardiology.

[85]  G. Shulman,et al.  Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. , 1997, Diabetes.

[86]  E. Gracely,et al.  The Effects of Low-Carbohydrate versus Conventional Weight Loss Diets in Severely Obese Adults: One-Year Follow-up of a Randomized Trial , 2004, Annals of Internal Medicine.

[87]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[88]  M. McGovern,et al.  Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). , 2003, The American journal of cardiology.

[89]  R. D'Agostino,et al.  Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. , 2003, Diabetes.

[90]  G. Reaven The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. , 2004, Endocrinology and metabolism clinics of North America.

[91]  W. Mitch,et al.  Nutritional Considerations in the Treatment of Patients with Chronic Uremia , 1998, Mineral and Electrolyte Metabolism.

[92]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[93]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[94]  S. Grundy,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Relationship between Generalized and Upper Body Obesity to Insulin Resistance in Asian Indian Men* , 2022 .

[95]  S. Ball,et al.  Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine. , 2003, The American journal of cardiology.

[96]  G. Reaven Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[97]  I. Piña,et al.  Resistance Exercise in Individuals With and Without Cardiovascular Disease , 2000 .

[98]  S. Teutsch,et al.  THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .

[99]  G. Hotamisligil,et al.  Inflammatory pathways and insulin action , 2003, International Journal of Obesity.

[100]  E. Ford,et al.  A comparison of the prevalence of the metabolic syndrome using two proposed definitions. , 2003, Diabetes care.

[101]  R. Nesto Correlation between cardiovascular disease and diabetes mellitus: current concepts. , 2004, The American journal of medicine.

[102]  Y. Aggoun,et al.  Obesity, Metabolic Syndrome, and Cardiovascular Disease , 2007, Pediatric Research.

[103]  A. Sanyal,et al.  Clinical aspects of fatty liver disease. , 2004, Seminars in liver disease.

[104]  Donald D Hensrud,et al.  Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.

[105]  Treatment of Obesity in Adults Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. , 1998, Obesity research.

[106]  J. Flier,et al.  Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. , 2004, Diabetes.

[107]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[108]  Morton B. Brown,et al.  The prevalence of the metabolic syndrome among arab americans. , 2004, Diabetes care.

[109]  J. Ordóñez‐Llanos,et al.  Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. , 2005, Diabetes care.

[110]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[111]  L. Groop,et al.  Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.

[112]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[113]  D. Raccah,et al.  Hypofibrinolysis and the insulin resistance syndrome. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[114]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[115]  T. Shoji,et al.  Decreased plasma adiponectin levels in young obese males. , 2003, Journal of atherosclerosis and thrombosis.

[116]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[117]  S. Haffner,et al.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.

[118]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[119]  David B Allison,et al.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.

[120]  A. Sniderman Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm , 2004, Current opinion in lipidology.

[121]  J. Brunzell,et al.  Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. , 2004, The Journal of clinical endocrinology and metabolism.

[122]  W. Buurman,et al.  Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. , 2004, The Journal of clinical endocrinology and metabolism.

[123]  A. Erbay,et al.  High prevalence of metabolic syndrome among young women with premature coronary artery disease , 2005, Coronary artery disease.

[124]  G. Shulman,et al.  Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.

[125]  Philip A Kern,et al.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. , 2003, Diabetes.

[126]  L. Niskanen,et al.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. , 2002, American journal of epidemiology.

[127]  Richard Hellman,et al.  American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[128]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[129]  S. Fowler,et al.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.

[130]  A. Bhargava A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study , 2003, Population health metrics.

[131]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[132]  M. Jensen,et al.  Influence of body fat distribution on free fatty acid metabolism in obesity. , 1989, The Journal of clinical investigation.

[133]  Robert L Hanson,et al.  Components of the "metabolic syndrome" and incidence of type 2 diabetes. , 2002, Diabetes.

[134]  S. Grundy Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. , 2002, Circulation.

[135]  Ken Williams,et al.  National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.

[136]  F. Pi‐Sunyer,et al.  Medical Hazards of Obesity , 1993, Annals of Internal Medicine.

[137]  D. Gaudet,et al.  Effect of obesity on HDL and LDL particle sizes in carriers of the null P207L or defective D9N mutation in the lipoprotein lipase gene: the Québec LipD Study , 2003, International Journal of Obesity.

[138]  S. Srinivasan,et al.  Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. , 2002, Journal of clinical epidemiology.

[139]  M. Yamasaki,et al.  Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[140]  G. Marchesini,et al.  WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[141]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[142]  Nathan D. Wong,et al.  Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.

[143]  B. Goodpaster,et al.  Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. , 2000, American journal of physiology. Endocrinology and metabolism.

[144]  Daniel E Casey,et al.  Metabolic issues and cardiovascular disease in patients with psychiatric disorders. , 2005, The American journal of medicine.

[145]  M. Marmot,et al.  Association of Early‐Onset Coronary Heart Disease in South Asian Men With Glucose Intolerance and Hyperinsulinemia , 1993, Circulation.

[146]  S. Haffner,et al.  Central adiposity determines prevalence differences of the metabolic syndrome. , 2003, Obesity research.

[147]  B. Horne,et al.  Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease? , 2004, Cardiology.

[148]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[149]  C. Ballantyne,et al.  Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S , 2001, Circulation.

[150]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[151]  Lisa J. Martin,et al.  Phenotypic, genetic, and genome-wide structure in the metabolic syndrome , 2003, BMC Genetics.

[152]  James W. Anderson,et al.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.

[153]  S. Grundy,et al.  Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[154]  S. Haffner,et al.  Comparison of the Associations of Apolipoprotein B and Non–High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study , 2004, Circulation.

[155]  P. Poulsen,et al.  Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. , 2005, Diabetes.

[156]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[157]  The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. , 2004, European heart journal.

[158]  Nader Rifai,et al.  Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.

[159]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[160]  Lawrence A Leiter,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines , 2006, Current opinion in cardiology.

[161]  S. Lévesque,et al.  Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease , 2003, Coronary artery disease.

[162]  P. Calverley,et al.  Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. , 2004, European heart journal.

[163]  M. Davidson,et al.  Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. , 2005, The American journal of cardiology.

[164]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[165]  M. Akbaba,et al.  Prevalence of the metabolic syndrome in a Turkish adult population. , 2004, Diabetes, nutrition & metabolism.

[166]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[167]  Fernando Costa,et al.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.

[168]  H. Parving,et al.  Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. , 2002, Diabetes.

[169]  A. Gotto,et al.  The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2004, The American journal of cardiology.

[170]  I. S. Wood,et al.  Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.

[171]  C. Lamendola,et al.  Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. , 2004, Metabolism: clinical and experimental.

[172]  C. Alessandri,et al.  Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. , 2005, The Journal of clinical endocrinology and metabolism.

[173]  N. Golden,et al.  in Women with , 1992 .

[174]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[175]  Jonathan C. Cohen,et al.  Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). , 2005, The American journal of cardiology.

[176]  R. Ross,et al.  Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. , 2002, The Journal of clinical endocrinology and metabolism.

[177]  S. Grundy Cholesterol gallstones: a fellow traveler with metabolic syndrome? , 2004, The American journal of clinical nutrition.

[178]  D. Matthews,et al.  Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[179]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[180]  D. Simonson,et al.  Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. , 2001, The Journal of clinical endocrinology and metabolism.

[181]  H. Lodish,et al.  Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines , 2004, Current opinion in lipidology.

[182]  R. Krauss,et al.  Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 , 2002, Journal of Lipid Research.